Antinociceptive effects induced by injection of the galanin receptor 1 agonist M617 into central nucleus of amygdala in rats

Neurosci Lett. 2012 Sep 20;526(1):45-8. doi: 10.1016/j.neulet.2012.07.041. Epub 2012 Aug 3.

Abstract

The present study was performed to explore the antinociceptive effects of M617, a selective galanin receptor 1 agonist, in the central nucleus of amygdala (CeA) of rats. Intra-CeA injection of 0.1 nmol, 0.5 nmol and 1 nmol of M617 induced dose-dependent increases in hindpaw withdrawal latencies (HWLs) to noxious thermal and mechanical stimulations in rats. Furthermore, rats received intra-CeA administration of M617 and galanin. The HWL to noxious thermal and mechanical stimulations increased markedly, and there were no significant differences in HWLs of rats received intra-CeA administration of M617 and galanin. The results demonstrated that intra-CeA injection of M617 induced significant antinociceptive effects in CeA of rats, indicating that galanin receptor 1 may be involved in M617-induced antinociception in the CeA of rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amygdala / drug effects*
  • Amygdala / physiopathology
  • Analgesics / pharmacology*
  • Analgesics / therapeutic use
  • Animals
  • Bradykinin / analogs & derivatives*
  • Bradykinin / pharmacology
  • Bradykinin / therapeutic use
  • Galanin / pharmacology*
  • Galanin / therapeutic use
  • Hot Temperature
  • Injections
  • Male
  • Pain / drug therapy*
  • Pain / physiopathology
  • Pain Measurement
  • Peptide Fragments / pharmacology*
  • Peptide Fragments / therapeutic use
  • Physical Stimulation
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Galanin, Type 1 / agonists*
  • Touch

Substances

  • Analgesics
  • M617 peptide
  • Peptide Fragments
  • Receptor, Galanin, Type 1
  • Galanin
  • Bradykinin